Citadel Advisors’s IGC Pharma IGC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-277,594
| Closed | -$78.1K | – | 13552 |
|
|
2025
Q4 | $78.1K | Sell |
277,594
-350,246
| -56% | -$125K | ﹤0.01% | 11811 |
|
|
2025
Q3 | $262K | Buy |
627,840
+356,874
| +132% | +$136K | ﹤0.01% | 10660 |
|
|
2025
Q2 | $82.9K | Buy |
270,966
+176,495
| +187% | +$53K | ﹤0.01% | 11472 |
|
|
2025
Q1 | $26.9K | Buy |
94,471
+91,403
| +2,979% | +$28.8K | ﹤0.01% | 12909 |
|
|
2024
Q4 | $1.03K | Buy |
+3,068
| New | +$1.15K | ﹤0.01% | 14232 |
|
|
2022
Q4 | – | Sell |
-15,583
| Closed | -$6.36K | – | 15140 |
|
|
2022
Q3 | $7K | Sell |
15,583
-113,607
| -88% | -$60.5K | ﹤0.01% | 12323 |
|
|
2022
Q2 | $69K | Buy |
129,190
+119,183
| +1,191% | +$75.2K | ﹤0.01% | 11714 |
|
|
2022
Q1 | $10K | Sell |
10,007
-46,789
| -82% | -$45.4K | ﹤0.01% | 13378 |
|
|
2021
Q4 | $55K | Sell |
56,796
-6,823
| -11% | -$9.15K | ﹤0.01% | 13193 |
|
|
2021
Q3 | $94K | Sell |
63,619
-14,017
| -18% | -$22.7K | ﹤0.01% | 12942 |
|
|
2021
Q2 | $127K | Buy |
77,636
+62,255
| +405% | +$95K | ﹤0.01% | 12685 |
|
|
2021
Q1 | $28K | Buy |
+15,381
| New | +$27.9K | ﹤0.01% | 13039 |
|
|
2020
Q3 | – | Sell |
-29,459
| Closed | -$29.9K | – | 10362 |
|
|
2020
Q2 | $18K | Buy |
+29,459
| New | +$16K | ﹤0.01% | 9567 |
|
|
2020
Q1 | – | Sell |
-14,735
| Closed | -$9K | – | 9850 |
|
|
2019
Q4 | $9K | Sell |
14,735
-27,496
| -65% | -$22.5K | ﹤0.01% | 9009 |
|
|
2019
Q3 | $41K | Buy |
42,231
+2,652
| +7% | +$3.19K | ﹤0.01% | 8759 |
|
|
2019
Q2 | $65K | Buy |
+39,579
| New | +$55.9K | ﹤0.01% | 8659 |
|
|
2018
Q3 | – | Sell |
-114,693
| Closed | -$57K | – | 9445 |
|
|
2018
Q2 | $57K | Sell |
114,693
-34,761
| -23% | -$20.1K | ﹤0.01% | 8414 |
|
|
2018
Q1 | $84K | Buy |
+149,454
| New | +$122K | ﹤0.01% | 7776 |
|
|
2017
Q4 | – | Sell |
-32,404
| Closed | -$12K | – | 8187 |
|
|
2017
Q3 | $12K | Buy |
32,404
+8,628
| +36% | +$3.2K | ﹤0.01% | 7428 |
|
|
2017
Q2 | $10K | Sell |
23,776
-67,680
| -74% | -$30.2K | ﹤0.01% | 7373 |
|
|
2017
Q1 | $43K | Buy |
91,456
+44,246
| +94% | +$14K | ﹤0.01% | 7079 |
|
|
2016
Q4 | $13K | Buy |
+47,210
| New | +$16.4K | ﹤0.01% | 7141 |
|
|
2016
Q2 | – | Sell |
-168,104
| Closed | -$87K | – | 7058 |
|
|
2016
Q1 | $87K | Buy |
168,104
+155,414
| +1,225% | +$47.1K | ﹤0.01% | 6080 |
|
|
2015
Q4 | $3K | Sell |
12,690
-18,195
| -59% | -$3.61K | ﹤0.01% | 8531 |
|
|
2015
Q3 | $6K | Buy |
30,885
+8,036
| +35% | +$2.18K | ﹤0.01% | 8595 |
|
|
2015
Q2 | $9K | Buy |
22,849
+4,464
| +24% | +$1.97K | ﹤0.01% | 8434 |
|
|
2015
Q1 | $8K | Sell |
18,385
-11,419
| -38% | -$6.18K | ﹤0.01% | 8241 |
|
|
2014
Q4 | $21K | Buy |
+29,804
| New | +$21.6K | ﹤0.01% | 7760 |
|
|
2014
Q2 | – | Sell |
-42,692
| Closed | -$34K | – | 8101 |
|
|
2014
Q1 | $34K | Buy |
42,692
+27,736
| +185% | +$24.1K | ﹤0.01% | 7008 |
|
|
2013
Q4 | $15K | Buy |
+14,956
| New | +$13.9K | ﹤0.01% | 6599 |
|
Other funds holding IGC
VCM
VFT
LC
Citadel Advisors's IGC Position: Q1 2026 in Review
Citadel Advisors sold out of IGC Pharma (IGC) in Q1 2026, closing a stake of 277,594 shares — an estimated $78.1K sold.
Citadel Advisors first reported a position in IGC in Q4 2013 and held it in 30 quarters. The position peaked at $262K in Q3 2025. 35 funds tracked by Wall St. Rank hold IGC as of Q1 2026.
- Citadel Advisors reported no remaining IGC Pharma position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 277,594 IGC Pharma shares in Q1 2026, an estimated $78.1K.
- Citadel Advisors first reported a position in IGC Pharma in Q4 2013 and held it in 30 quarters.
- Citadel Advisors's IGC Pharma position peaked at $262K in Q3 2025.
- 35 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.